Every Form 4 that Roivant Sciences Ltd. (ROIV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ROIV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ROIV filings page.
Roivant Sciences Ltd. reported insider share sales linked to director Daniel Allen Gold. QVT Financial Investment Cayman Ltd., where Gold is one of three directors, executed a series of open-market sales of Roivant common shares on February 11–13, 2026 at prices between $26.49 and $26.76 per share.
Individual transactions ranged from 150,000 to 425,000 common shares, with the last reported sale at $26.50 per share. Following the final transaction, 15,127,329 common shares were indirectly held by QVT Financial Investment Cayman Ltd. Gold shares voting and investment control over these shares and disclaims beneficial ownership beyond his pecuniary interest.
QVT Financial LP, acting as a director by deputization of Roivant Sciences Ltd., reported a series of indirect open‑market sales of Roivant common shares held by QVT Financial Investment Cayman Ltd. on February 11–13, 2026. The transactions included sales of 425,000, 150,000, 275,000, 150,784 and 225,000 common shares at prices between $26.49 and $26.76 per share. Following these trades, QVT Financial Investment Cayman Ltd. held 15,127,329 Roivant common shares indirectly for QVT Financial LP, while footnotes state that QVT Financial LP may be deemed to beneficially own 25,161,237 common shares across several related entities.
Sukhatme Mayukh reported multiple insider transaction types in a Form 4 filing for ROIV. The filing lists transactions totaling 1,954,674 shares at a weighted average price of $19.58 per share. Following the reported transactions, holdings were 18,836,547 shares.
Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. On January 20, 2026, he received an award of 609 Common Shares under the company’s Non-Employee Director Compensation Plan, which were fully vested on the grant date and recorded at $0 per share as a stock grant. On the same date, 122 Common Shares were withheld and forfeited at $22.98 per share through a net settlement to cover tax withholding obligations tied to the vesting of previously granted shares. After these transactions, he directly owned 109,030 Common Shares.
Roivant Sciences director Oren Ilan reported stock-based compensation and related tax withholding transactions. On 01/20/2026, he received 1,164 Common Shares at $0 under Roivant Sciences Ltd.'s Non-Employee Director Compensation Plan, and this award was fully vested on the grant date. On the same day, 124 Common Shares were withheld and settled at $22.98 per share to cover applicable tax obligations tied to the vesting and settlement of previously granted shares. After these transactions, he directly owned 119,428 Common Shares.
Roivant Sciences Ltd. director Melissa Epperly reported routine equity compensation activity. On January 20, 2026, she received an award of 815 Common Shares under Roivant’s Non-Employee Director Compensation Plan, which the footnotes state was fully vested on the grant date and issued at $0 per share as part of her director compensation.
On the same day, 54 Common Shares were withheld in a transaction coded “F” at $22.98 per share to cover tax withholding obligations tied to the vesting and settlement of previously granted shares. After these transactions, Epperly directly beneficially owned 57,665 Common Shares of Roivant Sciences.
Roivant Sciences Ltd. executive Eric Venker, President & Immunovant CEO, reported an option exercise and share sale. On January 12, 2026, he exercised stock options covering 200,000 Common Shares at an exercise price of $3.85 per share. That same day, he sold 200,000 Common Shares at a weighted average price of $21.92 per share, with individual sale prices ranging from $21.59 to $22.20.
After these transactions, Venker directly held 1,654,597 Common Shares and 5,244,834 stock options representing rights to buy additional Common Shares. The option award originally began vesting on April 20, 2022, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, subject to his continued service.
Roivant Sciences Ltd. director Dan Gold reported multiple sales of the company’s Common Shares made indirectly through QVT Financial Investment Cayman Ltd. On 12/16/2025, QVT FIC sold 275,000 Common Shares at a price of $22.93 per share and 642,282 Common Shares at $23.08 per share. On 12/17/2025, QVT FIC sold additional blocks of 432,718, 155,076, and 189,538 Common Shares at prices of $23.05, $23.02, and $23.17 per share, respectively.
Following these transactions, QVT FIC is reported to beneficially own 16,353,113 Roivant Common Shares, which are reported as indirectly owned by Gold through his role as one of three directors of QVT FIC. Gold disclaims beneficial ownership of these securities beyond his pecuniary interest.
Roivant Sciences Ltd. insider trading report: CEO and director Matthew Gline reported multiple transactions in Roivant common shares on 12/15/2025. He exercised stock options to buy 234,096 shares at $4.06 and a total of 3,636,563 shares at $12.68, then reported sales of 230,357, 566,116 and 943,527 shares at $21.68 per share. Additional share dispositions reflect “net settlement” of options to cover exercise prices. After these transactions, he reported beneficial ownership of 17,287,081 common shares held directly.
The filing notes that all options expiring in 2026 were exercised, eliminating that option position, and states that Gline has disgorged to Roivant the full amount of disgorgable profits from the sales as required by Section 16(b) of the Exchange Act.
Roivant Sciences director Vivek Ramaswamy reported large stock option exercises and related share sales in December 2025. On 12/11, 12/12 and 12/15, he exercised options at $12.68 per share to acquire 1,869,691, 4,672,724 and 832,453 common shares, respectively. On those same dates he sold 774,142, 1,975,858 and 353,745 shares at weighted average prices of $21.64, $21.96 and $22.05, and additional shares were disposed of through issuer net settlement to cover option exercise costs.
After these transactions, he beneficially owned 33,653,755 common shares directly and 13,357,857 shares indirectly through his spouse. The exercised options would have expired in March 2026 if not exercised and arise from awards that began vesting on December 27, 2019.
Immunovant, Inc. reported an insider transaction by a reporting person who is both a director and a 10% owner. On December 12, 2025, this filer purchased 16,666,666 shares of Immunovant common stock at $21 per share. Following the transaction, the filer directly beneficially owned 113,317,007 Immunovant shares. The filer is considered a director by deputization because senior executives of Roivant Sciences, Inc., a subsidiary of the reporting person, currently serve on Immunovant’s board on its behalf.
Roivant Sciences Ltd. officer Eric Venker, President & Immunovant CEO, reported equity transactions dated December 9, 2025. He exercised stock options to acquire 200,000 common shares at an exercise price of $3.85 per share, then sold 200,000 common shares at a weighted average price of $20.85 per share pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
After these transactions, he directly beneficially owned 1,497,908 common shares of Roivant Sciences. He also held 5,876,523 stock options exercisable into common stock at $3.85 per share, from a grant with a vesting commencement date of April 20, 2022 that vests 25% on the first anniversary and the remainder in 36 equal monthly installments, with an expiration date of April 19, 2032.
Roivant Sciences Ltd. (ROIV) reported an insider equity transaction by its Chief Financial Officer. On 11/20/2025, the CFO had 1,235 common shares withheld at a price of $20.27 per share. This was a "net settlement" of previously granted restricted stock units (RSUs) to cover tax withholding obligations when those RSUs vested and were settled.
After this tax-related share withholding, the CFO beneficially owns 388,273 common shares, held directly. The filing indicates this was an administrative equity compensation event, not an open-market purchase or sale.
Roivant Sciences Ltd. insider transaction: A Form 4 reports that officer Eric Venker, President & Immunovant CEO, had 7,051 common shares of Roivant Sciences Ltd. withheld on 11/20/2025 at a price of $20.27 per share. The filing explains this was a "net settlement" of previously granted restricted stock units (RSUs) by the company to cover applicable tax withholding when those RSUs vested and settled.
After this tax-related share withholding, Venker directly beneficially owns 1,497,908 common shares of Roivant Sciences Ltd. This type of transaction does not represent an open-market sale, but rather an administrative step tied to equity compensation vesting.
Roivant Sciences Ltd. (ROIV) director reported multiple indirect sales of common shares on 11/19/2025. The transactions were coded as open-market sales, with blocks of shares sold at prices between $20.16 and $20.25 per share through QVT Financial Investment Cayman Ltd.
Following these sales, the reporting person shows 18,047,727 Roivant common shares beneficially owned on an indirect basis through QVT Financial Investment Cayman Ltd. The filing notes that the individual is a shareholder of that entity but has no voting or investment control over it and expressly disclaims beneficial ownership of the reported shares beyond any pecuniary interest.
Roivant Sciences Ltd. (ROIV) director Dan Gold reported several open‑market sales of the company’s Common Shares on 11/19/2025. Indirectly through QVT Financial Investment Cayman Ltd., he sold 850,000 shares at $20.25, 150,000 shares at $20.20, 125,000 shares at $20.16, and 175,000 shares at $20.24, all coded as sales. Following these transactions, 18,047,727 Common Shares were beneficially owned indirectly, reported as held by QVT Financial Investment Cayman Ltd. The filing notes that Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership beyond his pecuniary interest.
Roivant Sciences Ltd. (ROIV) filed a Form 4 showing a significant shareholder-related sale of common shares. On 11/19/2025, an entity associated with QVT sold a total of 1,300,000 Roivant common shares in four open-market transactions at prices between $20.16 and $20.25 per share. After these sales, 18,047,727 common shares were reported as beneficially owned indirectly through QVT Financial Investment Cayman Ltd.
The explanation notes that QVT Financial LP and its related entities may be deemed to beneficially own 28,081,635 Roivant common shares in aggregate through several affiliated vehicles. QVT states that it disclaims beneficial ownership of these shares except to the extent of any pecuniary interest.
Roivant Sciences Ltd. director and more-than-10% owner Vivek Ramaswamy reported multiple open-market sales of the company’s common shares. On 11/13/2025 he sold 287,283 shares at a weighted average price of $20.81, on 11/14/2025 he sold 1,027,670 shares at a weighted average of $20.33, and on 11/17/2025 he sold 539,650 shares at a weighted average of $20.51. The prices reflect multiple individual trades within stated ranges for each day. After these transactions, he beneficially owned 33,653,756 common shares directly and 13,357,857 common shares indirectly through his spouse.
Roivant Sciences (ROIV): Officer Eric Venker reported an option exercise and same‑day sale. On 11/07/2025, he exercised 200,000 stock options at an exercise price of $3.85 per share (code M) and sold 200,000 common shares at a weighted average price of $20.22 (code S). Following these transactions, he reported 1,504,959 common shares beneficially owned directly and 6,076,523 derivative securities beneficially owned. The sales were made under a Rule 10b5‑1 trading plan adopted on March 28, 2025.
Venker is listed as President & Immunovant CEO. The options relate to an award with a vesting schedule beginning April 20, 2022, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continuous service.
Roivant Sciences (ROIV) director reported equity award. On 10/20/2025, a director acquired 1,056 Common Shares at $0, received as a fully vested grant under the Non-Employee Director Compensation Plan. After the award, the director beneficially owns 56,904 shares, held directly.
Roivant Sciences (ROIV) director James C. Momtazee reported routine equity activity on 10/20/2025. He received 789 Common Shares as a fully vested award under the company’s Non‑Employee Director Compensation Plan, recorded at $0 per share.
The company also executed a net settlement to cover taxes, withholding 158 shares at a price of $17.74. Following these transactions, Momtazee directly holds 108,543 Common Shares.
Roivant Sciences Ltd. (ROIV) reported insider activity by a director. On 10/20/2025, the director received 1,507 common shares under the Non-Employee Director Compensation Plan, which were fully vested on the grant date.
To cover tax withholding, the issuer executed a net settlement, withholding 281 shares at $17.74. After these transactions, the director directly owns 118,388 shares.
Roivant Sciences (ROIV) officer Eric Venker, President & Immunovant CEO, reported option exercises and open‑market sales. On 10/15–10/17/2025, he exercised 851,383 stock options at $15.85 and sold 851,383 common shares at weighted average prices of $16.93, $17.05, and $17.06, respectively. The transactions were executed under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following these trades, he beneficially owns 1,504,959 common shares directly.
Roivant Sciences (ROIV) — Form 4 insider transaction: President & Immunovant CEO Eric Venker reported option exercises and same‑day sales under a Rule 10b5‑1 plan. On 10/09/2025, he exercised 104,940 stock options at $15.85 (Code M) and sold 104,940 Common Shares at a weighted average price of $16.30 (Code S). On 10/13/2025, he exercised 20,727 options at $15.85 and sold 20,727 shares at a weighted average price of $16.25.
Following these transactions, beneficial ownership of Common Shares was 1,504,959 (direct). The options exercised were part of awards with a vesting commencement date of December 27, 2019, now fully vested, and an expiration date of March 31, 2026. The reported sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on March 28, 2025.
Insider transactions by Eric Venker at Roivant Sciences (ROIV) show multiple option exercises and open-market sales executed under a Rule 10b5-1 plan. Between 10/06/2025 and 10/08/2025, the reporting person exercised options at strike prices of $15.85, $7.45, and $3.85 and sold a total of 665,159 common shares at weighted-average prices reported up to $16.34. Following these transactions the filing reports beneficial ownership of 1,504,959 common shares. Several exercised option grants are described as fully vested or subject to stated vesting schedules.
Richard Pulik, Chief Financial Officer of Roivant Sciences Ltd. (ROIV) reported the disposition of 2,341 common shares on 09/28/2025 at a price of $15.17 per share. The Form 4 states this disposition represents a net settlement of previously granted restricted stock units (RSUs) to satisfy tax withholding obligations upon vesting. After the transaction, the reporting person beneficially owns 389,508 shares. The filing was signed on behalf of Mr. Pulik by an attorney-in-fact on 09/30/2025. All information is limited to the transaction details disclosed in the Form 4.
Roivant Sciences insider sale and post-transaction holding. The company's CFO and director, Richard Pulik, reported a disposition of 2,129 common shares on 09/20/2025 at a price of $15.04 per share. The filing states this disposition represents a "net settlement" to satisfy tax withholding related to previously granted RSUs. After the transaction Pulik beneficially owns 391,849 shares.
Roivant Sciences Ltd. (ROIV) insider filing shows Eric Venker, President & Immunovant CEO, reporting option awards and multiple share sales. The Form 4 discloses grants of stock options exercisable at $3.85 covering 1,562,374 options in total (1,000,000 on 09/19/2025; 462,374 and 100,000 on 09/22/2025) with an April 19, 2032 expiration and vesting tied to a 04/20/2022 commencement schedule. The filing also reports open-market sales totaling 1,711,000 common shares across 09/19–09/23/2025 at weighted-average prices disclosed in ranges (examples: $14.95, $14.99, $15.01, $14.83), some effected pursuant to a Rule 10b5-1 trading plan adopted June 25, 2024. Post-transactions, reported beneficial ownership figures for common stock and underlying options are shown on the form.